Graziela Jorge Polido

Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

Riccardo Masson, Maria Mazurkiewicz-Bełdzińska, Kristy Rose et al. · The Lancet Neurology · 2022 · 104 citations · Full text

Medicine, Neurology, Pharmacotherapy +6

Intragenic variants in the <i>SMN1</i> gene determine the clinical phenotype in 5q spinal muscular atrophy

Rodrigo de Holanda Mendonça, Ciro Matsui, Graziela Jorge Polido et al. · Neurology Genetics · 2020 · 46 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience

Rodrigo de Holanda Mendonça, Graziela Jorge Polido, Ciro Matsui et al. · Journal of Neuromuscular Diseases · 2020 · 38 citations

Medicine, Neurology, Neuroscience +17

Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen

Rodrigo de Holanda Mendonça, Graziela Jorge Polido, Matsui Ciro et al. · Journal of Neuromuscular Diseases · 2021 · 32 citations

Medicine, Neurology, Pharmacotherapy +17

Matching pairs difficulty in children with spinal muscular atrophy type I

Graziela Jorge Polido, Alessandra Ferreira Barbosa, Carlos H. Morimoto et al. · Neuromuscular Disorders · 2017 · 24 citations

Medicine, Neurology, Neuromuscular Disorders +2